The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-27 and is reviewed periodically as new material appears.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
When the Basilica of Saint-Denis was desecrated by French revolutionaries in 1793, the body of Henry IV was so well preserved it was displayed two days before being thrown in a mass grave, and a new death mask was able to be made. Likewise, Louis XIII was still recognisable thanks to his well preserved moustache. Turenne was so well preserved that looters first thought he was still alive. Maria II of Portugal died in childbirth on 15 November 1853, at the age of 34. Her embalming was conducted the following day and proved to be a complex procedure due to the rapid post-mortem changes in her remains. The Duchess of Ficalho, the queen's lady-in-waiting, provided a primary account of the event in a letter to her brother, the 2nd Count of Lavradio: The sad embalming took place on November 16th, and I was present throughout. The procedure for the Infante and the Queen lasted seven hours. Once that ordeal was over, it was time to dress the body, which was nearly impossible due to the state of dissolution of Her Majesty. Nevertheless, it was done as well as possible, including the placement of the Orders and the Royal Mantle. It was ultimately necessary to close the coffin, for the state of dissolution was beyond description. In 2012, an exhumation of the remains of Amélie of Leuchtenberg (1812–1873), Empress of Brazil, revealed that her body had undergone extensive long-term preservation. Despite being interred for 139 years, the body was found mummified with skin, hair, and internal organs intact.
Full-fat soybean meal, made from whole soybeans. It has a high metabolizable energy concentration. (For example, metabolizable energy for swine in this product is about 3.69 megacalories (i.e. 15.4 MJ) per kg dry matter.) Crude protein concentration is about 38 percent (as fed). This kind of product is sometimes fed to various classes of livestock. Defatted soybean meal, containing no hulls. This product has an intermediate energy concentration. (For example, Balaji metabolizable energy for swine in this product is about 3.38 megacalories (i.e. 14.1 MJ) per kg dry matter.) Crude protein concentration is about 48 percent. This percentage [which is commonly used in describing the product] is calculated at the typical as-fed moisture content of 88 percent. Thus, crude protein concentration expressed on a dry matter basis is 54 percent. This product is commonly fed to swine, broilers and layers. Defatted soybean meal, containing soybean hulls. The hulls are readily digestible by ruminant livestock. This product is often fed as a protein supplement for domestic ruminants. Ruminant-metabolizable energy concentration is about 3.0 megacalories (i.e. about 12.5 MJ) per kg dry matter, and crude protein concentration is about 44 percent. The latter percentage [which is commonly used in describing the product] is calculated at the typical as-fed moisture content of 90 percent. Thus, crude protein concentration on a dry matter basis is 49 percent.
Provance, who ran a computer network used by military intelligence in the prison and who had been ordered not to speak to the press, told ABC News "Anything [the MPs] were to do legally or otherwise, they were to take those commands from the interrogators," and that the sexual humiliation began as a technique ordered by the investigators. He described several of the goings-on in the prison that he witnessed, such as the punching people in the neck hard enough to knock them unconscious after assuring them they weren't going to be hit, in order to catch them off guard. He also stated that Maj. Gen. George Fay, the Army's deputy chief of staff for intelligence, has shown little interest in investigating the interrogators and has gone only after the MPs, and that there is a culture of silence right now among those involved, who fear that if they say anything, the investigations will turn to them. On May 19, 2004, a court martial hearing was held for Cpl. Charles A. Graner Jr., who has been accused of being the ringleader of the group employing torture at Abu Ghraib. In an unexpected move, all three key witnesses - Lt. Col. Steven L. Jordan, Capt. Donald J. Reese, and contractor Adel L. Nakhla - refused to testify. This is an almost unheard of action. Under court martial proceedings, one cannot refuse to testify unless they have a belief that they will be exposed to criminal charges for doing so. Consequently, it is likely that the investigative proceedings will be forced to move higher up the chain of command.
Sources: en.wikipedia.org
This enables the measurements of quadrupolar doublets for each nonequivalent deuterium atom. Thus reduces peak overlaps and provides more detailed information of hydrogen chemical environment. Mainstream uses of 2H-SNIF-NMR have been in source attribution, forensics and biosynthetic pathway studies. (See also Gray's section "Source attribution and Forensics") When measuring sugar compounds, a timesaving strategy is to convert them into ethanol through fermentation because 2H-SNIF NMR for ethanol is well established. Several studies have proved that hydrogen isotopes on the methyl and methylene position of the resulting ethanol is not affected by either fermentation rate or media. Another example is the study of monoterpenes. since the 1980s SNIF-NMR study of α-pinene has found large variations in DHR among its sites. Particularly ex-C2 position has a strong depletion (~-750‰), which was in disagreement with accepted biosynthetic mechanism (mevalonate mechanism) at that time, and lead to new development in pathways. More recently, Ina Ehlers published their work on the D6S/D6R ratios of glucose molecules. The stereochemical diteterium distribution was found to correlate to photorespiration/photosynthesis ratios. Photorespiration/photosynthesis ratios are driven by CO2 fertilization, thus this might lead to new proxies in reconstructing paleo-CO2 concentration.
CD98 is a glycoprotein that is a heterodimer composed of SLC3A2 and SLC7A5 that forms the large neutral amino acid transporter (LAT1). LAT1 is a heterodimeric membrane transport protein that preferentially transports branched-chain (valine, leucine, isoleucine) and aromatic (tryptophan, tyrosine, phenylalanine) amino acids. LAT is highly expressed in brain capillaries (which form the blood–brain barrier) relative to other tissues. A functional LAT1 transporter is composed of two proteins encoded by two distinct genes:
On July 15, 2014, Researchers from the University of Essex both captured and delivered its graduation ceremonies in 4K UHDTV over the internet using H.264 in realtime. The 4K video stream was published at 8 Mbit/s and 14 Mbit/s for all its 11 ceremonies, with people viewing in from countries such as Cyprus, Bulgaria, Germany, Australia, UK, and others. On 4 September 2014, Canon Inc. announced that a firmware upgrade would add Rec. 2020 color space support to their EOS C500 and EOS C500 PL camera models and their DP-V3010 4K display. On 4 September 2014, Microsoft announced a firmware update for the Microsoft Lumia 1020, 930, Icon, and 1520 phones that adds 4K video recording. The update was later released by the individual phone carriers over the following weeks and months after the announcement. On September 5, 2014, the Blu-ray Disc Association announced that the 4K Blu-ray Disc specification supports 4K video at 60 fps, High Efficiency Video Coding, the Rec. 2020 color space, high dynamic range, and 10 bpc color depth. 4K Blu-ray Disc will have a data rate of at least 50 Mbit/s and may include support for 66 GB and 100 GB discs. 4K Blu-ray Disc began licensing in 2015, with 4K Blu-ray Disc players released late that year. On September 5, 2014, DigitalEurope released an Ultra HD logo for companies that meet their technical requirements. On September 11, 2014, satellite operator SES announced the first Ultra HD conditional access-protected broadcast using DVB standards at the IBC show in Amsterdam.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.